<DOC>
	<DOCNO>NCT02282709</DOCNO>
	<brief_summary>Rationale : Chronic HCV infection characterise weak HCV specific CD8+ T cell response , due continuous pressure high viral load . Treatment chronic HCV patient ASV DCV result significant drop HCV viral load . At present , information available immunological effect treatment ASV DCV , early effect viral load reduction cause compound thought posse direct immunomodulatory effect . This information crucial well understanding mechanism may limit effectiveness treatment , occurrence viral rebound relapse , end treatment follow period . Objective : To evaluate detail functionality immune cell blood chronic HCV patient , treatment ASV DCV , IFN-free regimen . Study design : This investigator-initiated single center open label study one arm 12 patient . Study population : Adult chronic HCV patient genotype 1b , previous non-responders treatment . Intervention ( applicable ) : All patient treat twice daily 200 mg oASV daily 60 mg DCV 24 week . Main study parameters/endpoints : 1 . Phenotype function blood leukocytes treatment ; frequency HCV-specific T cell , NK cell monocytes 2 . Gene expression level leukocyte population , treatment 3 . Gene expression level type I IFN signal pathway whole blood sample 4 . Serum cytokine level use multiplex platform</brief_summary>
	<brief_title>Effect ASV DCV Therapy Quality Immune Status Chronic HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Patients 18 70 year age , chronic hepatitis C genotype 1b infection Patients nonresponders previous treatment peginterferon conventional interferon plus ribavirin combination therapy High viral load ( &gt; 400,000 IU/ml ) Indication antiviral therapy hepatitis C accord current clinical guideline Written inform consent Decompensated cirrhosis ( ChildPugh Grade B C ) Hepatic imaging ( ultrasound , CT MRI ) evidence hepatocellular carcinoma within last 3 month . Females pregnant breastfeed History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study Coinfections human immunodeficiency virus ( HIV ) Hepatitis B virus ( HBV ) Presence contraindication antiviral therapy ASV DCV : Interfering substance abuse , high alcohol intake ( indicator : 28 drinks/ week ) Any exposure NS3 protease inhibitor NS5A polymerase inhibitor Treatment peginterferon/ ribavirin within 6 month start therapy Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immunity</keyword>
</DOC>